艾蘆庫單抗
化合物
艾蘆庫單抗（INN：Icrucumab；開發代號：IMC-18F1）是一種人單克隆抗體，設計用於治療實體瘤。[1][2]艾蘆庫單抗由ImClone Systems公司開發，正在進行I期試驗。[3]
| 單克隆抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | VEGFR-1 |
| 臨床資料 | |
| 其他名稱 | IMC-18F1 |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1024603-92-6  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6514H10024N1756O2032S42 |
| 摩爾質量 | 146,796.63 g·mol−1 |
參考資料
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab (PDF). American Medical Association. [2024-01-21]. （原始內容存檔 (PDF)於2012-09-28）.
- ^ LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. April 2014, 32 (2): 303–11. PMID 23903897. S2CID 34756277. doi:10.1007/s10637-013-9998-8.
- ^ Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov